SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens  by Gupta, Vandana et al.
lsevier.com/locate/yviroVirology 347 (200SARS coronavirus nucleocapsid immunodominant T-cell epitope
cluster is common to both exogenous recombinant and endogenous
DNA-encoded immunogens
Vandana Gupta a, Tani M. Tabiin a, Kai Sun a, Ananth Chandrasekaran a, Azlinda Anwar a,
Kun Yang b, Priya Chikhlikar b, Jerome Salmon b, Vladimir Brusic c,d, Ernesto T.A. Marques b,e,f,
Srinivasan N. Kellathur a,b, Thomas J. August a,b,*
a Division of Biomedical Sciences, Johns Hopkins in Singapore, 31 Biopolis Way, #02-01 The Nanos, Singapore 138669, Singapore
b Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21205, USA
c Institute for Infocomm Research, 21 Heng Mui Keng Terrace, Singapore 119613, Singapore
d School of Land and Food Sciences and the Institute for Molecular Bioscience, University of Queensland, Brisbane 4072, Australia
e Department of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21218, USA
f Virology and Experimental Therapy Laboratory, Aggeu Magalhaes Research Center, Recife, PE 50670-420, Brazil
Received 11 August 2005; returned to author for revision 22 September 2005; accepted 22 November 2005
Available online 4 January 2006Abstract
Correspondence between the T-cell epitope responses of vaccine immunogens and those of pathogen antigens is critical to vaccine efficacy. In the
present study, we analyzed the spectrum of immune responses of mice to three different forms of the SARS coronavirus nucleocapsid (N): (1)
exogenous recombinant protein (N-GST) with Freund’s adjuvant; (2) DNA encoding unmodified N as an endogenous cytoplasmic protein (pN); and
(3) DNA encoding N as a LAMP-1 chimera targeted to the lysosomal MHC II compartment (p-LAMP-N). Lysosomal trafficking of the LAMP/N
chimera in transfected cells was documented by both confocal and immunoelectron microscopy. The responses of the immunized mice differed
markedly. The strongest T-cell IFN-g and CTL responses were to the LAMP-N chimera followed by the pN immunogen. In contrast, N-GSTelicited
strong T cell IL-4 but minimal IFN-g responses and a much greater antibody response. Despite these differences, however, the immunodominant T-
cell ELISpot responses to each of the three immunogens were elicited by the sameN peptides, with the greatest responses being generated by a cluster
of five overlapping peptides, N76–114, each of which contained nonameric H2
d binding domains with high binding scores for both class I and, except
for N76–93, class II alleles. These results demonstrate that processing and presentation of N, whether exogenously or endogenously derived, resulted
in common immunodominant epitopes, supporting the usefulness of modified antigen delivery and trafficking forms and, in particular, LAMP
chimeras as vaccine candidates. Nevertheless, the profiles of T-cell responses were distinctly different. The pronounced Th-2 and humoral response
to N protein plus adjuvant are in contrast to the balanced IFN-g and IL-4 responses and strong memory CTL responses to the LAMP-N chimera.
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Vaccines designed to prevent viral infection must promote
the adaptive expansion of T cells that are associated with B-
and T-cell long-term memory of epitopes identical to or cross-
reactive with those of the natural pathogen (Welsh et al., 2004;
Crotty and Ahmed, 2004). The processing and presentation of
antigen epitopes of vaccine immunogens must therefore mimic
that of pathogens. The conventional understanding has been6) 127 – 139
www.e
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endogenous cellular proteins that have been cleaved by
proteasomal and post-proteasomal peptidases (Villadangos et
al., 1999; Yewdell and Bennink, 2001; Kloetzel 2004) and that
the epitope loading of MHC class II molecules generally
involves exogenous proteins that are taken into antigen-
presenting cells (APCs) by specialized endocytic receptors
and processed by proteases of the endosomal/lysosomal
compartments (Moreno et al., 1991; Bryant and Ploegh, 2004).
It has been widely reported that various antigen-processing
pathways may affect immune epitope formation either posi-
tively or negatively and may influence the repertoire of T-cell
epitope-specific immune responses either quantitatively or
qualitatively (Pamer and Cresswell, 1998; Kessler et al.,
2002; Lautwein et al., 2004; Kloetzel, 2004). Such specificity
in antigen processing would suggest that the form and delivery
of an immunogen can be critical to the generation of
biologically effective antigen epitopes and thus to vaccine
efficacy. There is, however, abundant evidence for the
presentation of exogenous antigens by MHC class I and of
endogenous proteins by MHC class II through a variety of
alternative antigen trafficking and processing mechanisms,
including specialized processing pathways (Reimann and
Schirmbeck, 1999; Norbury et al., 2001; Bonifaz et al., 2002;
Imai et al., 2004), cross priming and presentation (Brode and
Macary, 2004; Tewari et al., 2005), alternative endolysosomal
pathways (Brooks et al., 1991; Lich et al., 2000; Chen and
Jondal, 2004), vesicular translocation (Reis e Sousa and
Germain, 1995; Ackerman and Cresswell, 2004), and phago-
cytic or autophagic mechanisms for antigen delivery to both the
MHC class I and II compartments (Houde et al., 2003;
Guermonprez et al., 2003; Nimmerjahn et al., 2003; Rocha
and Tanchot, 2004; Paludan et al., 2005).
Nevertheless, little is known about the consequences of
these alternative antigen trafficking and processing pathways
for the production of pathogen-specific antigen epitopes. Thus,
an examination of T-cell epitopes is a critical early step in the
development of a new generation of vaccines, including DNA
vaccines, chimeras with other protein sequences, or epitope-
based antigens, all of which involve antigens as non-viral
structures that may access processing pathways that differ from
those followed by the native pathogens. These issues regarding
the pathways used for antigen delivery and processing are
particularly relevant to MHC class II epitopes. Presentation of
antigen epitopes and activation of CD4 T cells by MHC class II
molecules are critical steps in generating memory B cell and
CD8+ T-cell phenotypes (Wang and Livingstone, 2003; Sun et
al., 2004), and failure to elicit immune memory is one of the
recognized problems of conventional genetic vaccines
(Maecker et al., 1998). This defect may reflect an inadequate
level of antigen expression or restricted access to the MHC II
processing and presentation compartments by DNA-encoded
endogenous antigens that lack a dedicated trafficking pathway
(Martins et al., 1995; Maecker et al., 1998; Oehen et al., 2000;
Rush et al., 2002).
In response to this problem, we have characterized DNA
vaccine constructs synthesized in the form of chimeras that linkthe antigen sequences to the trafficking/targeting signals of the
lysosome-associated membrane protein-1 (LAMP-1) (Chen et
al., 1985). LAMP molecules are known to traffic to lysosomes
and to specialized multilaminar vesicular compartments of
immature APCs, termed MIIC, where MHC II antigen
processing and the formation of antigenic peptide–MHC II
complexes occur (Kleijmeer et al., 1997; Geuze 1998; Murk et
al., 2004). Studies of several antigens (including HIV-1 Env
and Gag, HPV E7, cytomegalovirus pp65, carcinoembryonic
antigen, dengue preM/E and yellow fever Env, and the catalytic
subunit of the telomerase reverse transcriptase (hTERT))
expressed from viral vectors and naked DNA or RNA have
shown that LAMP-targeted antigens generated greater antigen-
specific lymphoproliferative activity, antibody titers, and
cytotoxic T-lymphocyte activities than do DNA constructs
encoding wild-type antigens (Rowell et al., 1995; Wu et al.,
1995; Ruff et al., 1997; Nair et al., 1998; Raviprakash et al.,
2001; Bonini et al., 2001; Su et al., 2002; Lu et al., 2003;
Marques et al., 2003; Chikhlikar et al., 2004; Barros de Arruda
et al., 2004; Anwar et al., 2005; Su et al., 2002). Most recently,
in a clinical study, patients who received dendritic cells
transfected with RNA encoding an hTERT/LAMP chimera
developed higher frequencies of hTERT-specific T-cell
responses than did subjects receiving dendritic cells transfected
with the unmodified hTERT template (Su et al., 2005).
Despite this abundance of evidence of increased immune
responses to LAMP chimeras of antigen proteins, the biolog-
ical consequences of the enhanced immune responses in
relation to protective immunity have not been defined, and
there remains a critical question of the identity of T-cell
epitopes of LAMP-targeted antigens as compared to those of
natural pathogens. LAMP trafficking is not a normal mecha-
nism for antigen access to the MHC class II compartment of
antigen-presenting cells, and the epitope specificity of antigen
processing and presentation in vivo in comparison to other
antigen delivery systems remains to be demonstrated.
In the present study, we have used the severe acute
respiratory syndrome coronavirus (SARS CoV) nucleocapsid
(N) as a model antigen to address this issue of immune
response and T-cell epitope presentation as a function of
antigen formulation. The N protein of 422 amino acids is
abundantly expressed and highly immunogenic (Lau et al.,
2004; Huang et al., 2004a). The primary function of this
structural protein in virus assembly is to bind to SARS CoV
RNA during the formation of the ribonucleoprotein complex
(Huang et al., 2004b). Previous studies have shown that both
the N protein (Lin et al., 2003; Zhao et al., 2005) and DNA
encoded N (Kim et al., 2004; Zhu et al., 2004; Yang et al.,
2004) elicit antibody and cytotoxic T-cell responses in mice. In
this analysis of the effect of immunogen formulation and
delivery on immune responses in vivo, we have utilized three
forms of N delivery: (1) recombinant N-GST protein combined
with Freund’s adjuvant as a classical exogenous antigen under
conditions of profound activation of the innate immune
response; (2) N encoded in a DNA plasmid as an unmodified
endogenous cytoplasmic/nuclear antigen; and (3) a DNA
construct with N inserted into the luminal domain of the entire
V. Gupta et al. / Virology 347 (2006) 127–139 129LAMP-1 molecule as an unnatural endogenous antigen
targeted to the luminal compartment of endosomal/lysosomal
vesicles (Guarnieri et al., 1993).
Results
Expression of N in cells transfected with p-N and p-LAMP-N
DNA plasmids
Validation of N expression by p-N and p-LAMP-N DNA
constructs was carried out by analyzing cells transfected in
vitro. cDNA encoding the N protein was prepared by RT-PCR
with N-specific primers and SARS RNA purified from a
Singapore clinical isolate (GenBank accession no. AY307165).
The corresponding 1269-bp N sequence was inserted into the
p43 vector (Kessler et al., 1996) to form the wild-type p-N
DNA expression vector and into the p43-hLAMP-1 construct
in a position 5V-proximal to the LAMP transmembrane domainFig. 1. Construction and expression of DNA plasmids encoding SARS CoV N and
levels in cell lysate and culture supernatant of transfected cells. (A) Schematic repres
various sequences: SARS CoV native nucleocapsid (SARS CoV N), hLAMP1 lum
domains (TM/cyto), and the adeno-associated virus inverted terminal repeat sequenc
luminal, transmembrane (TM) and cytoplasmic (cyto) domains in the p43 expressio
hLAMP-N: SARS CoV N sequences inserted into the full hLAMP1 sequence proxim
indicated. The ovals indicate the AAV-ITR sequences of the p43 plasmid. (B) N a
Western blot analysis of p-hLAMP (control), p-N and p-hLAMP-N-transfected ce
hLAMP-N protein in both the cell lysate and culture supernatant. The positions ofto make the p-hLAMP-N vector (Fig. 1A). Western blot
analysis of N in cell lysates and culture supernatants of
transfected COS-7 cells showed the presence of the ¨42 kDa N
protein at comparable levels in cell lysates and culture
supernatants of p-N and p-hLAMP-N-transfected COS-7 cells
and of various forms of the higher molecular weight LAMP-N
chimera in the cell lysate and culture supernatant of p-hLAMP-
N-transfected cells (Fig. 1B). The N-like protein in the cell
lysate of p-hLAMP-N-transfected cells is attributed to the
cleavage of N from the protease-resistant LAMP at some stage
in the cellular trafficking of the molecule. Intact or near-intact
HIV-1 Gag protein was also observed with cells transfected
with the corresponding LAMP/Gag DNA vaccine construct
(Marques et al., 2003). Several forms of the larger LAMP-N
molecule were also present in both the cell lysate and culture
supernatants of the transfected cells. The intact LAMP-N is
found at about 150 kDa, and the other bands are attributed to
various degradation products. However, we are cautious abouthLAMP-N. Transgenic N and hLAMP-N chimera are expressed at comparable
entation of the plasmid constructs. Arrows indicate the schematic position of the
inal domain (luminal domain), the hLAMP1 transmembrane and cytoplasmic
es (AAV ITR). p-hLAMP: a control plasmid encoding the full human LAMP1
n vector. p-N: the unmodified SARS CoV N sequence in the p43 plasmid. p-
al to the hLAMP TM domain. Boxed areas represent the open reading frames as
nd hLAMP-N protein expression in transfected monkey kidney COS-7 cells.
lls with anti-N-GST polyclonal serum showed comparable amounts of N and
the protein markers in kDa are shown on the right.
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experiments may have little relationship to the expression of
the immunogen in the cells transfected in vivo.
Confocal and immune electron microscopy
The presumed cell trafficking pathway for the newly
synthesized N, which lacks an endoplasmic reticulum translo-
cation (signal) sequence, is to the cell cytoplasm. In contrast,
the LAMP-N chimera is expected to traffic to endosomal/
lysosomal vesicles because of the LAMP vesicular trafficking
sequences. We used confocal microscopy to validate these
trafficking destinations for the immunoreactive unmodified N
antigens and N of the LAMP-N chimera expressed in
transfected mouse LB 27.4 B cells and human melanoma
Mel-Juso cells, comparing their cellular distribution to that of
the endogenously expressed LAMP-1 and MHC class II
proteins (Fig. 2). The colocalization of endogenous LAMP
and MHC class II proteins in vesicular compartments of APCs
has been extensively documented (Kleijmeer et al., 1996;
Geuze, 1998; Murk et al., 2004). Trafficking of the LAMP-N
chimera protein to the LAMP and MHC II compartments of the
transfected cells was validated by the colocalization of the
LAMP-N chimera (labeled by anti-N antibody) with endoge-
nous LAMP-1 and MHC class II in both mouse B (Figs. 2A–
F) and human melanoma (Figs. 2M–O) cells. Endogenous
MHC class II of the B cells was distributed both at the
periphery of the cell and in intracellular foci, in accordance
with the known maturation trafficking of vesicular MHC class
II molecules to the cell surface. Colocalization of LAMP-N
with MHC class II of B cells was restricted to the intracellular
foci in the endosomal–lysosomal compartment and not with
the mature MHC class II at the plasma membrane (Figs. 2D–Fig. 2. Colocalization (yellow) of confocal images of immunolabeled transgenic N
murine B cells (A–F) and with MHC II in human Mel-Juso cells (M–O). ColocalF). MHC class II and LAMP-N in transfected melanoma cells
were both densely present throughout the cytoplasm and were
markedly colocalized (Figs. 2M–O). Unmodified N was
densely expressed throughout the cytoplasm of the transfected
cells, again in apparently vesicular structures, but with little or
no colocalization with either the endogenous LAMP-1 (Figs.
2G–I) or MHC class II (Figs. 2J–L) in B cells or melanoma
cells (Figs. 2P–R).
Greater definition of the localization of N in transfected
cells was obtained by analyzing of immunolabeled ultrathin
cryosections of mouse LB 27.4 B cells. The endocytic
compartments of these B cells are morphologically similar to
those of other reported mouse B-cell lines (6H5.DM and
A20.Ab), with well-defined multivesicular and multilaminar
MIICs and end organelles (Geuze, 1998). Double immunogold
labeling of the transfected B cells confirmed that N of the
LAMP-N chimera was present with both endogenous LAMP
and MHC class II molecules in the MIIC multilaminar vesicles
(Figs. 3A, B). In contrast, unmodified N was predominantly
localized in the cytoplasm or in vacuolated structures with no
evident colocalization with LAMP or MHC class II (Figs. 3C–
E). Remarkably, lower power magnification showed that some
of the cytoplasmic vesicles contained large amounts of N.
These vesicles may correspond to the strongly labeled vesicular
structures shown by immunofluorescent microscopy, and the
presence of N in these structures suggests a possible route for
the secretion of the protein (Fig. 3E).
Mouse primary immune responses
N antigen in three forms, representing differences in antigen
delivery, adjuvants, and peptide processing pathways, were
administered according to the following protocols: (1) N as an(red) with LAMP1 (green) and MHC II (green) in p-hLAMP-N-transfected
ization rarely seen in p-N-transfected cells (G–L, P–R).
Fig. 3. Immunoelectron microscopy of murine B cells transfected with p-LAMP-N and p-N. N of p-hLAMP-N-transfected cells localized in typical MIIC
multilaminar vesicles with endogenous LAMP (A) and MHC II (B). N of p-N-transfected cells not found with endogenous LAMP1 (C) or MHC II (D) but present as
aggregates in cytoplasmic vesicles devoid of LAMP1 and MHC class II, sometimes in large numbers (E, low power). MIIC, MHC class II containing compartment;
PM, plasma membrane; L, electron dense lysosomes. Scale bar was adjusted to 200 nm.
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day one and 3 and 6 weeks later, initially with CFA and then
with IFA. (2) N as an unmodified endogenous, DNA-encoded,
cytoplasmic protein, and (3) N as an artificial chimera encoded
in the luminal domain of LAMP and targeted to cellular
lysosomal and MHC II compartments were administered five
times, on day 1, and 3, 6, 9, and 14 weeks later, without added
adjuvant but subject to the molecular adjuvant effects of the
DNA CpG motifs and the targeting of the LAMP-N chimera to
the MHC II compartment. DNA encoding p-hLAMP was used
as the negative control.
T-cell responses were assayed by IFN-g ELISpot and
ELISA assays using spleen cells collected 8 days after the
final DNA immunization. For these assays, the T cells were
stimulated with N-His protein as a positive control or with a
library of overlapping N peptides, 15 to 20 amino acids in
length. The results were confirmed in three experiments and in
multiple assays with three independent sets of peptides from
different sources. The IFN-g responses were also assayed with
an ELISA protocol, with similar results (data not shown). Thestrongest IFN-g responders were cells from mice immunized
with p-hLAMP-N, with comparable but weaker responses by
the p-N-immunized mice, and minimal responses by cells of
the N-GST-immunized mice (Table 1; Fig. 4). The major
grouping of IFN-g responses was elicited by peptides of amino
acid sequence N76–114, encompassing 5 of the overlapping
peptides. More recently, these results have also been confirmed
in a new experimental protocol currently being conducted that
also show that all of the peptides that encompass N76–114 elicit
both CD4- and CD8-specific ELISpot responses (data not
shown). Other dominant responses were to peptides N130–149
and N241–258 and the overlapping peptides N352–366 and
N353–370. All significant epitope-specific responses of the pN or
N-GST-immunized mice were shared by the p-hLAMP-N-
immunized mice. The weak IFN-g responses of the N-GST
protein immunized mice were observed only with peptides that
elicited the strongest responses with splenocytes of the DNA-
plasmid-immunized mice (Figs. 4A–C). This comparatively
weak IFN-g response of N-GST-immunized mice was in marked
contrast to the strong IL-4 responses as shown below and to the
Table 1
T-cell IFN-g ELISpot positive N-peptide sequences
N peptides IFN-g SFC/106 splenocytes (meanTSD)
Number N-aa Sequence p-hLAMP-N p-N N-GST
11 76–93 NTNSGPDDQIGYYRRATR 57T2 3T2 6T1
12 80–99 GPDDQIGYYRRATRRVRGGD 429T8 266T18 46T12
13 84–101 QIGYYRRATRRVRGGDGK 377T11 209T6 55T6
14 92–109 TRRVRGGDGKMKELSPRW 309T13 212T7 24T5
15 100–114 GKMKELSPRWYFYYL 75T12 55T7 9T2
21 130–149 GIVWVATEGALNTPKDHIGT 106T4 61T8 5T3
35 241–258 QQQGQTVTKKSAAEASKK 131T20 23T3 2T1
51 352–366 ILLNKHIDAYKTFPP 137T10 34T8 38T4
52 353–370 LLNKHIDAYKTFPPTEPK 118T11 50T8 46T11
All ELISpot responses were to a group of 9 dominant peptides, shown by peptide number, amino acid region in N, sequence, and number of IFN-g-positive cells of
mice immunized with the three immunogens. A cluster (N76 – 114) of 5 peptides of 15 to 20 aa, overlapping by 10 to 16, contains 3 of the strongest dominant epitopes.
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titers to N-GST immunization on day 42 (after the first boost)
was 1:25,000 and at day 63 (after the second boost) was
1:67,500, as compared to titers increasing to a maximum of
1:3200 on days 84 and 105 in response to immunization with the
p-N and p-hLAMP-N DNA constructs.
Memory immune responses
Memory immune responses (total IgG antibody titers, CTL
activity, and ELISpot IFN-g and IL-4 responses) were
examined by use of a separate experimental protocol with
groups of mice treated with the same three N antigen
preparations but receiving only three inoculations over 6
weeks. After an interval of 36 weeks, the memory immune
response was activated by a single injection at week 42 of the
p-N construct as a surrogate of virus infection. Antibody and T-
cell ELISpot and CTL responses were measured immediately
before p-N injection at 42 weeks and three times at week
intervals thereafter (Figs. 5 and 6). The T-cell assays were
conducted with the selected peptides that had elicited immu-
nodominant responses in pilot experiments for IFN-g, N80–99
and N241–258; IL-4, N80–99 and N130–149; and CTL, N80–99
and N353–370. The residual T-cell IFN-g and IL-4 responses of
mice sacrificed on day 1 before p-N memory activation were
very low and were significant only in mice initially immunized
with p-hLAMP-N (Fig. 5). Following the recall p-N injection,
increased IFN-g and IL-4 responses were observed on day 8,
reaching an apparent maximum on days 15 to 22. The strongest
memory T-cell responses in all assays were those of mice
initially immunized with p-hLAMP-N, with strong IFN-g and
IL-4 responses to both peptides. N-GST plus Freund’s adjuvant
elicited strong IL-4 responses but minimal IFN-g responses, as
seen for the primary response. The responses of mice initially
immunized with p-N were uniformly lower than those seen for
the LAMP chimera and the IL-4 responses to N-GST.
However, the IFN-g responses were greater for p-N than for
N-GST. Memory CTL responses were strongest in p-hLAMP-
N-immunized mice, with a much weaker response to p-N DNA
immunization and little if any after immunization with N-GST
with adjuvant (Fig. 6). Memory antibody responses followed
the pattern of the primary response, with a much stronger IgGtiter of about 1:25,000 on days 15 and 22 following activation
of the N-GST-immunized mice as compared to the responses of
about 1:7000 by the p-hLAMP-N-immunized mice. There was
relatively little response (1:1000) by mice initially immunized
with p-N.
Correlation of ELISpot-positive peptides and computational
predictions of N-specific H2d binding motifs
Peptide epitope activation of T cells relies on receptor
(TCR) recognition of complexes of antigen peptide sequences
bound to the nine amino acids of the binding clefts of MHC
class I and II molecules (Benacerraf, 1978). It is postulated that
the kinetic stability of the MHC–peptide complexes is a key
parameter that dictates immunodominance (Lazarski et al.,
2005). In the further analysis of the T-cell epitope specificity of
N, the predicted H2d class I (H2-Kd, -Ld, -Dd) and class II (I-
Ed, I-Ad) binding motifs of the 60 SARS N overlapping
peptides were examined by a murine immunoinformatics
system based on quantitative matrices, PREDBALB/c (Zhang
et al., 2005). Each of the 414 nine-amino-acid sequences of N
was analyzed for binding to the core sequence of the 5 H2d
alleles. All of the nine IFN-g ELISpot-positive peptides scored
for a high probability of binding to class I and/or class II alleles
(Table 2), and, in ongoing experiments, all of a new set of
peptides encompassing N76–114 elicit both CD4- and CD8-
specific responses (data not shown).
Discussion
In the present study, we have demonstrated that the
dominant T-cell immune responses of mice immunized with
the SARS CoV N protein plus adjuvant or with DNA encoding
two different cellular trafficking forms of N are directed to the
same peptide epitopes of all three immunogens. This finding
points to the existence of versatile antigen-processing mechan-
isms that are not defined by the initial site of delivery of the
protein, whether exogenous or endogenous, or the state of the
innate responses to the immunogens. The data are consistent
with multiple in vivo routes for antigen access to proteolytic
processing compartments that produce the same or comparable
MHC I and II peptide epitopes. This versatility would not
Fig. 4. Primary T-cell IFN-g ELISpot responses of (A) p-hLAMP-N, (B) p-N,
and (C) N-GST-immunized mice. As described in Materials and methods, mice
were immunized five times with the DNA immunogens and three times with N-
GST plus adjuvant, and the mice were sacrificed for ELISpot assay of antigen-
specific splenocyte IFN-g secretion 8 days after the final immunization. The
splenocytes were stimulated with recombinant N-His protein and with N
peptides from panels of overlapping peptides spanning the entire molecule,
with mice immunized by hLAMP plasmid as the negative control. All
significant T-cell peptide-specific IFN-g responses elicited by each immunogen
were stimulated by the same peptides, with the strongest responses to p-
hLAMP-N and the weakest to N-GST.
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result of differences in the levels of antigen, the degree of
processing, or access to cellular compartments for antigen
presentation. For example, in this study, the greater response
to the LAMP-N chimera could be related to the quantita-
tively greater delivery of N to the MHC class II compart-
ment of APCs. There can also be major differences in the
repertoire or functionality of T cells responding to any given
epitope, such as the differences in the IFN-g and IL-4
responses of mice immunized with DNA or with N-GSTplus CFA. Others have reported similar findings that the
same CTL-defined epitope peptide is generated by an
exogenous protein and by plasmid DNA-encoded antigens
(Schirmbeck et al., 1998) and that the efficiency of MHC
class I cross-presentation of peptides derived from exogenous
antigens is comparable to that for presentation by the
classical MHC class II pathway (Storni and Bachmann,
2004). Additionally, Ria et al. (2004) have compared the
response to hen egg-white lysozyme (HEL) and its reduced
and carboxymethylated form (RCM-HEL) and have found
that RCM-HEL induces an in vivo T-cell response that is
focused on the same immunodominant determinant that
characterizes the response to native HEL but that the
RCM-HEL response is skewed toward the Th1 pathway.
No difference in the efficiency of processing was observed
between HEL and RCM-HEL. We conclude that the makeup
of the T-cell epitopes of an antigen is primarily determined
by the amino acid composition of the protein in the context
of the peptide binding sites of MHC molecules, and not by
the mechanism of delivery of the protein. These findings
support the usefulness of novel immunogens, such as antigen
chimeras and DNA vaccines encoding antigens with modified
cell trafficking signals, as vaccine candidates, despite their
differences from normal pathogen proteins in terms of
antigen structure, delivery, and processing mechanisms.
The differences in the results we obtained for the three
antigen preparations were largely related to the character and
magnitude of the immune responses. Mice immunized with
exogenous N protein plus Freund’s adjuvant responded with a
greatly enhanced antibody response and a high ratio of T-cell IL-
4 to IFN-g responses to the antigen peptides. In contrast, the
same peptides elicited a balanced IFN-g and IL-4 response and
lower antibody responses in mice immunized with DNA
vaccines. Freund’s adjuvant has been associated with the
preferential induction of T-cell Th2 responses (Shibaki and
Katz, 2002; Yip et al., 1999; Billiau and Matthys, 2001), and
different T-cell cytokine responses to the same epitope (Varga et
al., 2000) have been attributed to variable expression patterns of
single cells and populations that reflect transient rather than
heritable differences in the expression profile (Kelso and
Groves, 1997; Kelso et al., 2002). Another difference between
the vaccines was the comparatively poor memory response to
the N-GST protein and p-N DNA construct as compared to the
p-hLAMP-N chimera construct. The limited efficacy of the
conventional p-N DNA construct is consistent with many
previous studies of our and other laboratories (Martins et al.,
1995;Maecker et al., 1998; Oehen et al., 2000; Rush et al., 2002;
Marques et al., 2003; Barros de Arruda et al., 2004). Although it
is likely that there are multiple factors involved in memory T-cell
differentiation (Masopust et al., 2004), we attribute the enhanced
T-cell and memory responses to p-LAMP-N, at least in part, to
the increased efficiency of trafficking of the LAMP-N chimera
to the MHC II compartments of APCs.
The localization of the dominant T-cell responses to a cluster
of overlapping peptides epitopes within N76–114 is similar to
findings from other ongoing studies of HIV-1 Gag and yellow
fever virus envelope proteins where the major T-cell responses
Fig. 5. Kinetics of memory IFN-g and IL-4 ELISpot responses of N-immunized mice. Mice were immunized three times over 6 weeks with p-hLAMP
(control 0), p-N (n), p-hLAMP-N (r), N-GST (). At week 42, after an interval of 8 months, the memory immune response was activated by a single
injection of the p-N construct. Mice were sacrificed 1 day before the final p-N injection and three times at weekly intervals thereafter (days 1, 8, 15, and 22).
All assays were conducted in triplicate with cells from each of three mice from each experimental group and at each time point. ELISpot IFN-g memory was
measured in response to N80 – 99 (A) and N241 – 258 (B); and IL-4 in responses to N80 – 99 (C) and N130 – 149 (D). The p-hLAMP-N immunogen elicited the
strongest IFN-g and IL-4 ELISpot memory T-cell responses. N-GST immunogen elicited strong IL-4, but little IFN-g response.
V. Gupta et al. / Virology 347 (2006) 127–139134also involve clustered epitopes (unpublished observations).
Regions of overlapping T-cell epitopes are also reported in
studies of HIV-1 proteins (Shankar et al., 1996; Surman et al.,
2001; Brown et al., 2003; Berzofsky et al., 1991), the outer
membrane protein of Chlamydia trachomatis (Kim and
DeMars, 2001), and in predictions of HLA T-cell epitopes
(Srinivasan et al., 2004; Zhang et al., 2005). Clustered T-cell
epitopes appear to be a common, perhaps ubiquitous occurrenceFig. 6. Kinetics of memory CTL responses of N-immunized mice. Mice were imm
hLAMP (control 0), p-N (n), p-hLAMP-N (r), and N-GST (). CTL activity w
immunogen elicited the strongest memory CTL responses with relatively little respoand, as such, may facilitate the development of epitope-based
vaccines if a single or few hot spots elicit all of the required T-
cell functions. The basis for such hot spots is unknown but is
likely to be related in some measure to the binding affinities of
the peptide sequences to MHC molecules as well as to other
functional parameters that affect MHC–peptide binding to T-
cell receptors during T-cell activation (Chen et al., 2005).
Analysis of the nonameric MHC binding motifs of SARS N byunized and investigated under the same protocol as described in Fig. 5 with p-
as assayed in responses to N80 – 99 (A) and N353 – 370 (B). The p-hLAMP-N
nse of mice immunized with N-GST protein or DNA encoding unmodified N.
Table 2
Correlation of ELISpot-positive peptides and computational predictions of N-specific H2d binding motifs
IFN-g N peptides PREDBALB/c H2d alleles
H2-Kd H2-Ld H2-Dd I-Ad I-Ed
76NTNSGPDDQIGYYRRATR93 – – SGPDDQIGY – –
80GPDDQIGYYRRATRRVRGGD99 YYRRATRRV GPDDQIGYY IGYYRRATR GYYRRATRR GYYRRATRR
GYYRRATRR
84QIGYYRRATRRVRGGDGK101 YYRRATRRV – IGYYRRATR GYYRRATRR RRVRGGDGK
GYYRRATRR
92TRRVRGGDGKMKELSPRW109 – – GGDGKMKEL – RRVRGGDGK
VRGGDGKMK
GKMKELSPR
100GKMKELSPRWYFYYL114 ELSPRWYFY LSPRWYFYY LSPRWYFYY – GKMKELSPR
SPRWYFYYL LSPRWYFYY
130GIVWVATEGALNTPKDHIGT149 ALNTPKDHI VWVATEGAL – EGALNTPKD WVATEGALN
TEGALNTPK
241QQQGQTVTKKSAAEASKK258 – – – QQGQTVTKK –
GQTVTKKSA
VTKKSAAEA
TKKSAAEAS
352ILLNKHIDAYKTFPP366 LLNKHIDAY – – NKHIDAYKT LLNKHIDAY
NKHIDAYKT
353LLNKHIDAYKTFPPTEPK370 LLNKHIDAY – – NKHIDAYKT LLNKHIDAY
NKHIDAYKT
The N-specific H2d binding motifs were analyzed by the PREDBALB/c system. Each of the IFN-g ELISpot peptides contained multiple nine amino acids binding
motifs that were within the top 5% of all binding scores to the five H2d alleles. All of the IFN-g ELISpot peptides except N241 – 258 scored were predicted to contain
class I binding motifs. Similarly, class II binding motifs were predicted in all except N76 – 93 and N130 – 149.
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predicting the probability of binding of each nine-amino-acid
sequence of an antigen to the H2d class I (H2-Kd, -Ld, -Dd)
and class II (I-Ed, I-Ad) binding motifs (Zhang et al., 2005)
showed that each of the SARS N peptides that elicited
ELISpot-positive IFN-g T-cell responses contained high-
probability binding motifs for MHC class I and/or II alleles.
There may also be protein structural effects in the selection of
epitope hot spots. The three-dimensional structure of the N
amino-terminal domain, N45–181, of a truncated model lacking
N1–44 and N182–422 has been determined by NMR spectros-
copy (Huang et al., 2004b). Two of the ELISpot-positive
sequences, N76–114 and N130–149, were present on the exposed
surface of this structure. The N76–114 T-cell hot spot sequence
also contains the N76–101 sequence reported to comprise a B
cell epitope (Huang et al., 2004a). An association between T-
and B-cell epitopes has also been found for the HIV envelope;
these are seen to be present in exposed loops or strands when
mapped onto the crystal structure of the protein (Brown et al.,
2003; Del Porto et al., 2002; Shirai et al., 1999).
Materials and methods
Cell lines
Mouse B lymphoma and monkey kidney cell lines (LB27.4
and COS-7) were obtained from ATCC (Rockville, MD).
Human melanoma cell line (Mel-Juso) was obtained from
German Collection of Microorganisms and Cell Cultures
(Braunschweig Germany). Insect cell lines SF9 and High5
were obtained from Invitrogen. All the cell lines were
maintained according to the supplier’s protocols.SARS CoV N DNA plasmids
The SARS CoV nucleocapsid (N) cDNAwas prepared from
a Singapore clinical isolate and purified total RNA. The 1269 bp
N gene sequence was obtained by PCR with primers 5V-
CGGCTAGCATGTCTGATAATGGACCCCAATC-3V and 5V-
GCGGTACCTTATGCCTGAGTTGAATCAGCAG-3V, having
NheI and KpnI sites. The PCR product was cloned into the p43
expression vector containing AAV-ITR sequences flanking the
expression elements and a CMV promoter (Kessler et al., 1996)
to make the wild-type plasmid p-N. This N-sequence (without
the stop codon) was amplified, and XholI and EcoRI sites were
introduced by using primers 5V-CGCTCGAGATGTCTGA-
TAATGGACCCCAATC-3V and 5V-CGGAATTCTGCCT-
GAGTTGAATCAGCAGAA-3V. The p-hLAMP-N chimera
vector was constructed by substitution of the HIV-gag sequence
into the p-hLAMP-gag vector (Chikhlikar et al., 2004). Due to
the presence of internal NheI or XhoI sites in the N sequence,
the p-N and p-hLAMP-N plasmids were constructed by
sequential cloning of the two fragments of the N gene.
E. coli and baculovirus N-expression systems
SARS-CoV N was amplified from the RT-PCR sequence
using forward primer 5V-ACGTCAGAATTCATGTCTGA-
TAATGGACCCCAA with an EcoRI site and reverse primer
5V-AGTTTAGCGGCCGCTGCCTGAGTTGAATCAGCAG
with a NotI site. The cDNA sequence was cloned into the
EcoRI and NotI sites of the pGEX6P-1 (Invitrogen, a kind gift
from Dr. Roland of the Institute of Molecular and Cell Biology,
Singapore) and pFastBac HT-A (Invitrogen, Carlsbad, CA)
vectors. All clones were verified by sequencing.
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Expression of the N protein from the vaccine plasmids p-N
and p-LAMP-N in the COS-7 cell line was analyzed by
Western blot analysis. Cells were transfected with the SARS
plasmids using Polyfect Transfection reagent (Qiagen GmBH).
Cell culture and polyacrylamide gel electrophoresis were
carried out as described (Chikhlikar et al., 2004). The N
protein was detected by incubation with polyclonal serum from
mice immunized with N-GST protein followed by horseradish-
peroxidase-conjugated goat anti-mouse IgG monoclonal anti-
body (Pierce Biotechnology). Binding of secondary antibody
was visualized with the SuperSignal West Pico Chemilumi-
nescent Kit or DAB (Pierce Biotechnology).
Recombinant N protein expression, purification, and Western
blot analysis
Recombinant N protein was generated by use of two DNA
plasmid expression systems, N-GST in E. coli for use as an
antigen for mouse immunization and N-His in a baculovirus
system as an antigen for ELISA and ELISpot assays.
Recombinant N protein was expressed as a GST fusion in
Top10 E. coli cells (Invitrogen) after IPTG induction. The
protein was purified by affinity chromatography with glutathi-
one S–Sepharose beads (Amersham Pharmacia Biotech AB),
and the preparation was validated by Western blot analysis
using mouse monoclonal anti-GST (Santa Cruz Biotechnology)
and rabbit polyclonal anti-N (Imgenex) antibodies. The Bac to
Bac baculovirus expression system version C (Invitrogen) was
used for N protein expression in insect cells. pFastBacHT-A-N
was constructed by cloning the EcoRI- and NotI-digested
SARS CoV N fragment into the pFastBacHT-A vector. N
protein was purified from lysates of infected High5 cells using
Ni-NTA agarose beads (Invitrogen), and the protein prepara-
tion was verified by Western blot analysis with mouse
monoclonal Penta-His-antibody (Qiagen, GmBH) and anti-N
(Imgenex) antibodies. Purification of the culture products of
each expression system yielded fractions enriched for the 73-
kDa N-GST and 55-kDa N-His proteins.
Immunofluorescent confocal and immunoelectron microscopy
The cellular localization of the expressed viral proteins in
transfected mouse B lymphoma cells was studied by confocal
and immunoelectron microscopy and confirmed by confocal
microscopy of transfected human Mel-Juso cells. Cells were
transfected with the SARS CoV plasmids (p-hLAMP-N and p-
N) using Polyfect (Qiagen, GmBH). The expression of the
recombinant viral proteins was visualized by the use of rabbit
polyclonal anti-N (Imgenex) or mouse monoclonal anti-human
LAMP1 antibody H4A3 (obtained from supernatant of
hybridoma cultures prepared in our laboratory). Localization
of the transgenic proteins in MHC-class-II-containing compart-
ments and lysosomes of B cells was determined by the use of
anti-mouse MHC class II antibody M5/114.15.2 (BD Bios-
ciences) and anti-mouse LAMP1 (mLAMP1) ID4B antibody(prepared in our laboratory). Localization of the viral proteins
in the MHC class II-containing compartments of Mel-Juso cells
was analyzed with anti-HLA-DR, DP, and DQ antibodies (BD
Pharmingen) and rabbit anti-N antibody (IMG-549; Imgenex).
Mouse immunization
Three immunization protocols were carried out: (1) three
groups (p-hLAMP control, p-N, and p-hLAMP-N immuno-
gens) of 5 female (6 to 8 weeks old) BALB/c mice per group
were immunized subcutaneously at the base of the tail with 50
Ag of specified endotoxin-free DNA plasmid diluted in PBS on
days 1, 22, 43, 64, and 100. Blood samples were collected by
phlebotomy from the tail vein on days 0, 21, 42, 63, 84, 99, and
108, and the animals were sacrificed on day 108, 8 days after
the last immunization. (2) Another group was immunized
intraperitoneally with 10 Ag of N-GST protein emulsified with
CFA followed by two booster immunizations 3 weeks apart
with N-GST protein emulsified with IFA. Blood samples were
collected as outlined above on days 0, 21, and 42, and the
animals were sacrificed on day 50, 8 days after the last
immunization. Protocols 1 and 2 were carried out twice with
five mice per group each time. (3) An additional protocol was
carried out for analysis of memory responses: four groups of 16
mice each (p-hLAMP control, p-N, p-hLAMP-N, and N-GST
immunogens) were immunized as outlined above, but with
only three injections over 6 weeks. At week 42, after an
interval of 36 weeks, the memory immune response was
activated by a single injection of the p-N construct with p-
hLAMP as the negative control. Three mice of each group were
sacrificed 1 day before the final p-N injection and at weekly
intervals for 3 weeks thereafter. These experiments were
performed as approved by the Johns Hopkins University
Animal Care and Use Committee under Protocol Number
MO04M178.
ELISA for N-specific antibody analysis
Anti-SARS CoV N IgG antibodies in the serum from each
mouse were assayed by ELISA for seroconversion at a dilution
of 1:300, and the total IgG titers of 3-fold serial dilutions,
starting from 1:100, were determined by standard quantitative
ELISA. In brief, ELISA plates (96-well, MaxiSorb F96; Nunc
Inc.) were coated overnight at 4 -C with 1 Ag/ml recombinant
N-His protein in PBS followed by blocking with ELISA buffer
(PBS containing 2.5% milk and 0.05% Tween 20). After
washing, appropriately diluted mouse serum was added and
incubated for 2 h at room temperature. Total IgG was detected
with the Mouse Extravidin alkaline phosphatase staining kit
(Sigma).
ELISpot analysis of antigen-activated T cells
The response of antigen-specific T cells from immunized
mice was measured by the use of IFN-g and IL-4 ELISpot sets
(BD Pharmingen) according to the manufacturer’s protocol.
Splenocytes were stimulated with 5 Ag/ml of recombinant N-
V. Gupta et al. / Virology 347 (2006) 127–139 137His (baculovirus-produced) or 10 Ag/ml of the overlapping
SARS CoV synthetic peptides from three sources (NIH AIDS
Research and Reference Reagent Program, Rockville, MD;
SynPep Corp, Dublin, CA; the Johns Hopkins Biochemistry
Core Facility). Negative control stimulation produced less than
five spots per well in >90% of experiments. The average
number of spots in the negative control wells was 1.67T1.87.
Each experiment was repeated at least twice on different groups
of mice from two immunizations.
Cytotoxic T-lymphocyte assay
CTL assays were performed using the Cytotox 96 non-
radioactive cytotoxicity assay kit (Promega Corporation, USA).
The pooled splenocytes (from two mice in the N-GST group
and three mice in each of the other groups) obtained at each
time point (days 1, 8, 15, and 22) after memory recall with pN
were stimulated in vitro with each of the two peptides, N80–99
and N353–370, at a final concentration of 10 Ag/ml for 4 days.
SP2/O target cells were pulsed overnight separately with 10 Ag/
ml of each of the two peptides, washed two times, resuspended
in RPMI supplemented with 2% FCS, and seeded onto a 96-
well U-bottom plate (1104 cells/well in 50 Al of culture
medium) with an equal volume of pooled, in-vitro-stimulated
splenocytes from recalled mice (effector cells) at different
effector/target ratios, 20:1, 40:1, and 80:1. All incubations were
done in quadruplicate. The negative control contained an equal
concentration of unrelated peptide, and controls for effector cell
spontaneous release, target spontaneous release, and target
maximum release were included in the assays. All the values
were computed as the meanT standard deviations of the four
replicate assays after subtracting the average of the values
obtained for the negative controls. The use of overlapping
peptides for antiviral CD8 and CD4 T-cell responses has been
described (Maecker et al., 2001; Draenert et al., 2003).
Prediction of T-cell binding motifs
BALB/c mouse H2d T-cell binding motifs of the 60
overlapping N peptides were predicted by use of the
PREDBALB/c class I (H2-Kd, -Ld, -Dd) and class II (I-Ed, -Ad)
models (Zhang et al., 2005). The PREDBALB/C system scores
the binding index of all immunogen nine-amino-acid sequences
to H2d molecules, based on quantitative matrices.
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